Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
N-Ethylhexedrone
N-Ethylhexedrone is a stimulant1 in the substituted cathinone class2 with a short duration of action.2 It was first synthesized by Boehringer Ingelheim in 19643 and appears to have entered the online research chemical market in late 2015. Users report euphoric effects resembling those of crack cocaine and α-PVP, particularly when snorted or vaporized. Recreational misuse is associated with compulsive redosing and addictive behavior.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Pharmacology
Pharmacodynamics
N-Ethylhexedrone inhibits dopamine and norepinephrine reuptake4, increasing their concentrations in the synapse by slowing their clearance. It inhibits the dopamine transporter more potently than the norepinephrine transporter, with reported IC50 values of 0.0467 μM and 0.0978 μM, respectively.5
Pharmacokinetics
Based on its structure and presumed similarity to other cathinones, N-Ethylhexedrone is likely metabolized through N-dealkylation or reduction of the carbonyl group followed by N-dealkylation.6
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Noradrenergic stimulants, Dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
ModerateChronic N-ethylhexedrone use is described as moderately addictive, with high abuse potential and psychological dependence in some users. Compulsive redosing can lead to excessive binges, including reported use lasting several days; repeated dosing may increasingly serve to avoid the comedown.
Physical
Cravings and unspecified withdrawal symptoms may occur when people who have developed addiction abruptly stop using N-ethylhexedrone.
Toxicity
N-ethylhexedrone has been identified in post-mortem findings7 from overdose cases, without an established lethal-dose threshold. Its exact toxic dose is unknown.
Observations and internet self-reports concerning N-ethylhexedrone include increased heart rate and blood pressure, abnormal heartbeat, and vasoconstriction, although effects are difficult to distinguish from those of co-administered substances.6
Intranasal N-ethylhexedrone use has been associated with pain, nasal discharge, bleeding, and temporarily obstructed breathing; chronic intranasal use may cause tissue damage.
In a screening using cultured SH-SY5Y cells and yeast, N-ethylhexedrone appeared to have the greatest cytotoxicity among five tested cathinones.
Psychosis Risk
Compulsive N-ethylhexedrone use extending over several days without sleep is associated with a high chance of psychosis and paranoia. Psychotic symptoms generally appear after at least one missed night of sleep, although very heavy use within a single day can trigger paranoia and hallucinations.
Seizure Risk
N-ethylhexedrone is considered likely to increase seizure susceptibility, and people with epilepsy are advised to avoid it.
History & Culture
Early pharmaceutical development
N-Ethylhexedrone was first synthesized by the German pharmaceutical company Boehringer Ingelheim in 1964 and patented that year as a potential appetite suppressant. The patent described its synthesis alongside other aminoketone derivatives.6 It belonged to a series
Legality
International
1961 Single Convention on Narcotic Drugs: not scheduled; an exact-name and exact-identity search of the complete current INCB Yellow List found no N-ethylhexedrone (2-(ethylamino)-1-phenylhexan-1-one) entry.
1971 Convention on Psychotropic Substances: scheduled in Schedule II as N-ethylhexedrone; this confirms, rather than disproves, the packet's legacy Schedule II claim.
1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances: not listed in either precursor Table I or Table II; an exact-name and exact-identity search of the complete current INCB Red List found no entry.
By Country
References
Citations
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the N-Ethylhexedrone article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.